Deutsch English Français

Contact

EP0951295

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP0951295

EP0951295 - COMPOSITIONS FOR USE IN INHIBITING OF ALPHA-V-BETA3 MEDIATED ANGIOGENESIS [Right-click to bookmark this link]
Former [1999/43]	METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ANGIOGENESIS
	[2009/04]
Status	No opposition filed within time limit Status updated on 15.04.2011 Database last updated on 11.05.2024
Most recent event Tooltip	15.04.2011	No opposition filed within time limit	published on 18.05.2011 [2011/20]
Applicant(s)	For all designated states THE SCRIPPS RESEARCH INSTITUTE 10550 North Torrey Pines Road La Jolla, CA 92037 / US
	[2010/23]
Former [1999/43]	For all designated states The Scripps Research Institute 10550 North Torrey Pines Road La Jolla, CA 92037 / US
Inventor(s)	01 / BROOKS, Peter Apartment 6113 3550 Lebon Drive San Diego, CA 92122 / US
	02 / CHERESH, David, A. 2108 Sea Village Circle Cardiff, CA 92007 / US
	[2003/28]
Former [2000/41]	01 / BROOKS, Peter Apartment 6113 3550 Lebon Drive San Diego, CA 92122 / US
	02 / CHERESH, David, A. 2108 Sea Village Circle Cardiff, CA 92007 / US
	03 / SILLETTI, Steven, Dr., Scripps Research Institute 10550 N Torrey Pines Road La Jolla, CA 92037 / US
Former [1999/43]	01 / BROOKS, Peter Apartment 6113 3550 Lebon Drive San Diego, CA 92122 / US
	02 / CHERESH, David, A. 2108 Sea Village Circle Cardiff, CA 92007 / US
Representative(s)	Fisher, Adrian John Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[N/P]
Former [1999/43]	Fisher, Adrian John CARPMAELS & RANSFORD 43 Bloomsbury Square London WC1A 2RA / GB
Application number, filing date	97928698.6	30.05.1997
	[1999/43]
	WO1997US09158
Priority number, date	US19960018733P	31.05.1996 Original published format: US 18733 P
	US19960015869P	31.05.1996 Original published format: US 15869 P
	[1999/46]
Former [1999/43]	US19960018773P	31.05.1996
	US19960015869P	31.05.1996
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO9745137
	Date:	04.12.1997
	Language:	EN
	[1997/52]
	Type:	A1 Application with search report
	No.:	EP0951295
	Date:	27.10.1999
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 04.12.1997 takes the place of the publication of the European patent application.
	[1999/43]
	Type:	B1 Patent specification
	No.:	EP0951295
	Date:	09.06.2010
	Language:	EN
	[2010/23]
Search report(s)	International search report - published on:	US	04.12.1997
	(Supplementary) European search report - dispatched on:	EP	13.06.2000
Classification	IPC:	A61K38/48, A61K39/00, A61P7/00, A61P35/00, A61K31/12	[2009/04]
	CPC data not yet available
	Former IPC [1999/43]	A61K38/48, A61K39/00
Designated contracting states	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [1999/43]
Extension states	AL	13.11.1998
	LT	13.11.1998
	LV	13.11.1998
	RO	13.11.1998
	SI	13.11.1998
Title	German:	ZUSAMMENSTELLUNGEN ZUR VERWENDUNG ALS ALPHA-V-BETA3 VERMITTELTER ANGIOGENESIS HEMMERS	[2009/04]
	English:	COMPOSITIONS FOR USE IN INHIBITING OF ALPHA-V-BETA3 MEDIATED ANGIOGENESIS	[2009/04]
	French:	COMPOSITIONS POUR L'UTILISATION AFIN D'INHIBER L'ANGIOGENESE MEDIEE PAR ALPHA-V- BETA3	[2009/04]
	Former [1999/43]	VERFAHREN UND ZUSAMMENSTELLUNGEN ZUR UNTERDRÜCKUNG VON ANGIOGENESIS
	Former [1999/43]	METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ANGIOGENESIS
	Former [1999/43]	PROCEDES ET COMPOSITIONS INHIBANT L'ANGIOGENESE
Entry into regional phase	13.11.1998	National basic fee paid
	13.11.1998	Search fee paid
	13.11.1998	Designation fee(s) paid
	13.11.1998	Examination fee paid
Examination procedure	16.12.1997	Request for preliminary examination filed International Preliminary Examining Authority: US
	17.11.1998	Examination requested [1999/43]
	24.10.2001	Amendment by applicant (claims and/or description)
	07.11.2002	Despatch of a communication from the examining division (Time limit: M06)
	27.03.2003	Reply to a communication from the examining division
	10.10.2003	Despatch of a communication from the examining division (Time limit: M04)
	03.02.2004	Reply to a communication from the examining division
	31.03.2005	Despatch of communication that the application is refused, reason: substantive examination {1}
	16.05.2008	Despatch of a communication from the examining division (Time limit: M04)
	04.08.2008	Reply to a communication from the examining division
	17.11.2009	Communication of intention to grant the patent
	18.02.2010	Fee for grant paid
	18.02.2010	Fee for publishing/printing paid
Appeal following examination	27.05.2005	Appeal received No. T1127/05
	28.07.2005	Statement of grounds filed
	15.01.2008	Result of appeal procedure: continuation of examination procedure
	15.01.2008	Date of oral proceedings
	22.01.2008	Minutes of oral proceedings despatched
	15.01.2008	Date of oral proceedings
Opposition(s)	10.03.2011	No opposition filed within time limit [2011/20]
Fees paid	Renewal fee
	13.11.1998	Renewal fee patent year 03
	15.05.2000	Renewal fee patent year 04
	14.05.2001	Renewal fee patent year 05
	14.05.2002	Renewal fee patent year 06
	13.05.2003	Renewal fee patent year 07
	13.05.2004	Renewal fee patent year 08
	12.05.2005	Renewal fee patent year 09
	23.03.2006	Renewal fee patent year 10
	14.05.2007	Renewal fee patent year 11
	28.03.2008	Renewal fee patent year 12
	12.05.2009	Renewal fee patent year 13
	31.03.2010	Renewal fee patent year 14
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]WO9528426 (JOLLA CANCER RES FOUND [US]) [X] 1,6-10,17-23,29-45 * the whole document *;
		[PX]WO9714716 (MERCK PATENT GMBH [DE], et al) [PX] 1,6-10,17-23,29-45 * the whole document *;
		[PX]EP0770622 (MERCK PATENT GMBH [DE]) [PX] 1,6-10,17-23,29-45* the whole document *;
		[X] - H P HAMMES ET AL., "Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization", NATURE MEDICINE., CO US, (199605), vol. 2, no. 5, pages 529 - 533, XP002138522 [X] 1,6-10,17-23,29-45 * the whole document * DOI: http://dx.doi.org/10.1038/nm0596-529
		[X] - P C BROOKS ET AL., "Integrin alphaV beta3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels", CELL, NA US, (19941230), vol. 79, pages 1157 - 1164, XP002138523 [X] 1,6-10,17-23,29-45 * the whole document * DOI: http://dx.doi.org/10.1016/0092-8674(94)90007-8
		[X] - M FRIEDLANDER ET AL., "Definition of two antagonists pathways by distinct alphaV integrins", SCIENCE., AAAS. LANCASTER, PA., US, (19951201), vol. 270, pages 1500 - 1502, XP000867841 [X] 1,6-10,17-23,29-45 * the whole document * DOI: http://dx.doi.org/10.1126/science.270.5241.1500
		[X] - P C BROOKS ET AL., "Requirement of vascular integrin alphaV beta3 for angiogenesis", SCIENCE., AAAS. LANCASTER, PA., US, (19940422), vol. 264, pages 569 - 571, XP002138524 [X] 1,6-10,17-23,29-45 * the whole document * DOI: http://dx.doi.org/10.1126/science.7512751
		[X] - R A CLARK ET AL., "Transient functional expression of alpha.v.beta.3 on vascular cells during wound repair", CHEMICAL ABSTRACTS, (19960701), vol. 125, no. 1, Database accession no. 7248, XP002138525 [X] 1,6-10,17-23,29-45
		[ ] - AM. J. PATHOL., (199605), vol. 148, no. 5, pages 1407 - 1421 [ ] * abstract *
	International search	[Y] - EUR. J. CANCER, 1996, Vol. 32A, No. 1, TIMAR et al., "The Antimetabolite Tiazofurin(TR) Inhibits Glycoconjugate Biosynthesis and Invasiveness of Tumor Cells", pages 152-159.
		[Y] - CIRCULATION, November 1994, Vol. 90, No. 5, MATSUNO et al., "Inhibition of Integrin Function by a Cyclic RGD-Containing Peptide Prevents Neointima Formation", pages 2203-2206.
	Examination	WO9706791
		- HOOD JD ET AL., "Differential alpha-v integrin-mediated Ras-ERK signaling during two pathways of angiogenesis", JOURNAL OF CELL BIOLOGY, (20030901), vol. 162, no. 5, pages 933 - 943

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p